Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 234Neoplasms 206Carcinoma, Non-Small-Cell Lung 100Colorectal Neoplasms 98Prostatic Neoplasms 93Lung Neoplasms 78Multiple Myeloma 53Melanoma 51Pancreatic Neoplasms 50Head and Neck Neoplasms 49Neoplasm Metastasis 47Leukemia, Myeloid, Acute 43Carcinoma, Hepatocellular 43Ovarian Neoplasms 39Brain Neoplasms 39Squamous Cell Carcinoma of Head and Neck 36Recurrence 35Glioblastoma 33Uterine Cervical Neoplasms 32Sarcoma 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Glioma 29Lymphoma, Non-Hodgkin 28Lymphoma 27Colonic Neoplasms 27Stomach Neoplasms 26Carcinoma, Renal Cell 26Lymphoma, Follicular 25Esophageal Neoplasms 24Rectal Neoplasms 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cystadenocarcinoma, Serous × 90 days × Clear all
NCT04814108 2026-03-18

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 2 Completed
92 enrolled

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡